Cargando…
Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed fluorodeoxyglucose accumulations along the right pleura in area...
Autores principales: | Tanaka, Takaaki, Asakura, Shoji, Hisamatsu, Kazuya, Fujimoto, Nobukazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251556/ https://www.ncbi.nlm.nih.gov/pubmed/35795882 http://dx.doi.org/10.1016/j.jtocrr.2022.100351 |
Ejemplares similares
-
An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020) -
Spare the lung: surgical treatment approach for malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2023) -
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020) -
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020) -
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)